Considering that the Hb is involved in the regulation of monoamines, such as those modulated by drug therapy, and the current evidence on the possibility of reducing the reward value of aggressive behavior by increasing neuronal firing in the LHb, one could envision further exploring this innovative technique to selectively deliver nanodroplets to the LHb and modulate its activity, to reduce aggressive behavior in patients with psychiatric disorders that do not present adequate response to conventional therapy. This evidence concerns the gene GSTM1 and psychiatric disorder.